Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis

The clustering of high levels of LDL cholesterol (LDL-C) and other risk factors represents a predisposing condition for atherosclerotic disease development. Cardiovascular prevention is based on effective control of these conditions. In adult subjects with mild hypercholesterolemia we compared in th...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2017-10, Vol.27 (10), p.850-857
Main Authors: Trimarco, V., Battistoni, A., Tocci, G., Coluccia, R., Manzi, M.V., Izzo, R., Volpe, M.
Format: Article
Language:English
Subjects:
Adult
Aged
Armolipid Plus
Biomarkers - blood
Blood Glucose - drug effects
Blood Glucose - metabolism
Blood Pressure - drug effects
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Cardiovascular prevention
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Dietary Supplements - adverse effects
Female
Glycated Hemoglobin A - metabolism
Humans
Hypercholesterolemia
Hypercholesterolemia - blood
Hypercholesterolemia - complications
Hypercholesterolemia - diagnosis
Hypercholesterolemia - drug therapy
Hypolipidemic Agents - adverse effects
Hypolipidemic Agents - therapeutic use
Insulin - blood
Italy
LopiGLIK
Male
Middle Aged
Morus - chemistry
Nutraceuticals
Phytotherapy
Plant Extracts - adverse effects
Plant Extracts - isolation & purification
Plant Extracts - therapeutic use
Plants, Medicinal
Risk Factors
Single-Blind Method
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clustering of high levels of LDL cholesterol (LDL-C) and other risk factors represents a predisposing condition for atherosclerotic disease development. Cardiovascular prevention is based on effective control of these conditions. In adult subjects with mild hypercholesterolemia we compared in the real life the effects of a new combination of nutraceuticals on lipid and glucose metabolism and blood pressure with those of an established nutraceutical combination. This multicenter, controlled, randomized, single-blind trial was designed to compare the effect of Armolipid Plus® versus that of LopiGLIK® on lipid and glucose levels and blood pressure (BP) in subjects with mild hypercholesterolemia not on statin therapy. Primary outcome was the proportion of subjects achieving therapeutic targets of LDL-C (
ISSN:0939-4753
1590-3729
DOI:10.1016/j.numecd.2017.08.003